A Phase 3, Multi-Center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine.

Trial Profile

A Phase 3, Multi-Center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Bacterial meningitis; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 17 Dec 2012 The extension study has been completed according to the ClinicalTrials.gov record (NCT00856297).
    • 17 Dec 2012 The extension study has been completed according to the ClinicalTrials.gov record (NCT00856297).
    • 02 May 2012 Planned end date of the extention trial (NCT00856297) is changed from Jul 2012 to Oct 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top